AU2001249345A1 - Identification of essential genes in prokaryotes - Google Patents
Identification of essential genes in prokaryotesInfo
- Publication number
- AU2001249345A1 AU2001249345A1 AU2001249345A AU4934501A AU2001249345A1 AU 2001249345 A1 AU2001249345 A1 AU 2001249345A1 AU 2001249345 A AU2001249345 A AU 2001249345A AU 4934501 A AU4934501 A AU 4934501A AU 2001249345 A1 AU2001249345 A1 AU 2001249345A1
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- gene product
- seq
- nos
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000894006 Bacteria Species 0.000 title description 33
- 108700039887 Essential Genes Proteins 0.000 title description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 718
- 102000039446 nucleic acids Human genes 0.000 claims description 710
- 108020004707 nucleic acids Proteins 0.000 claims description 709
- 108090000623 proteins and genes Proteins 0.000 claims description 587
- 239000002773 nucleotide Substances 0.000 claims description 359
- 125000003729 nucleotide group Chemical group 0.000 claims description 359
- 238000000034 method Methods 0.000 claims description 356
- 230000000692 anti-sense effect Effects 0.000 claims description 249
- 230000000694 effects Effects 0.000 claims description 204
- 150000001875 compounds Chemical class 0.000 claims description 190
- 230000035755 proliferation Effects 0.000 claims description 142
- 230000014509 gene expression Effects 0.000 claims description 123
- 229920001184 polypeptide Polymers 0.000 claims description 112
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 112
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 112
- 238000012360 testing method Methods 0.000 claims description 87
- 230000002401 inhibitory effect Effects 0.000 claims description 79
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 230000000295 complement effect Effects 0.000 claims description 43
- 239000012634 fragment Substances 0.000 claims description 36
- 230000008236 biological pathway Effects 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 21
- 230000012010 growth Effects 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 239000003242 anti bacterial agent Substances 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 230000001235 sensitizing effect Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 108091092724 Noncoding DNA Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 288
- 239000000047 product Substances 0.000 description 285
- 241000588724 Escherichia coli Species 0.000 description 97
- 241000894007 species Species 0.000 description 78
- 244000285963 Kluyveromyces fragilis Species 0.000 description 74
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 74
- 241000222126 [Candida] glabrata Species 0.000 description 74
- 241000186779 Listeria monocytogenes Species 0.000 description 73
- 241000191967 Staphylococcus aureus Species 0.000 description 58
- 241000607142 Salmonella Species 0.000 description 50
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 42
- 241001138501 Salmonella enterica Species 0.000 description 41
- 241000194032 Enterococcus faecalis Species 0.000 description 40
- 241000588747 Klebsiella pneumoniae Species 0.000 description 40
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 40
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 40
- 229940032049 enterococcus faecalis Drugs 0.000 description 40
- 229940023064 escherichia coli Drugs 0.000 description 40
- 241000607766 Shigella boydii Species 0.000 description 38
- 241000607764 Shigella dysenteriae Species 0.000 description 38
- 241000607760 Shigella sonnei Species 0.000 description 38
- 229940007046 shigella dysenteriae Drugs 0.000 description 38
- 229940115939 shigella sonnei Drugs 0.000 description 38
- 241001225321 Aspergillus fumigatus Species 0.000 description 37
- 241000193738 Bacillus anthracis Species 0.000 description 37
- 241000588832 Bordetella pertussis Species 0.000 description 37
- 241000589513 Burkholderia cepacia Species 0.000 description 37
- 241000589875 Campylobacter jejuni Species 0.000 description 37
- 241000222122 Candida albicans Species 0.000 description 37
- 241000144583 Candida dubliniensis Species 0.000 description 37
- 241000222173 Candida parapsilosis Species 0.000 description 37
- 241000222178 Candida tropicalis Species 0.000 description 37
- 241000606161 Chlamydia Species 0.000 description 37
- 241001647372 Chlamydia pneumoniae Species 0.000 description 37
- 241000186216 Corynebacterium Species 0.000 description 37
- 201000007336 Cryptococcosis Diseases 0.000 description 37
- 241000221204 Cryptococcus neoformans Species 0.000 description 37
- 241000588697 Enterobacter cloacae Species 0.000 description 37
- 241000194031 Enterococcus faecium Species 0.000 description 37
- 241000606768 Haemophilus influenzae Species 0.000 description 37
- 241000590002 Helicobacter pylori Species 0.000 description 37
- 241001293418 Mannheimia haemolytica Species 0.000 description 37
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 37
- 241000186362 Mycobacterium leprae Species 0.000 description 37
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 37
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 37
- 241000588650 Neisseria meningitidis Species 0.000 description 37
- 241000187678 Nocardia asteroides Species 0.000 description 37
- 241000235645 Pichia kudriavzevii Species 0.000 description 37
- 241000588767 Proteus vulgaris Species 0.000 description 37
- 241000533331 Salmonella bongori Species 0.000 description 37
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 37
- 241000607762 Shigella flexneri Species 0.000 description 37
- 241000191963 Staphylococcus epidermidis Species 0.000 description 37
- 241000194019 Streptococcus mutans Species 0.000 description 37
- 241000589884 Treponema pallidum Species 0.000 description 37
- 241000607447 Yersinia enterocolitica Species 0.000 description 37
- 241000607479 Yersinia pestis Species 0.000 description 37
- 229940091771 aspergillus fumigatus Drugs 0.000 description 37
- 229940065181 bacillus anthracis Drugs 0.000 description 37
- 229940095731 candida albicans Drugs 0.000 description 37
- 208000032343 candida glabrata infection Diseases 0.000 description 37
- 229940055022 candida parapsilosis Drugs 0.000 description 37
- 229940047650 haemophilus influenzae Drugs 0.000 description 37
- 229940037467 helicobacter pylori Drugs 0.000 description 37
- 229940007042 proteus vulgaris Drugs 0.000 description 37
- 229940098232 yersinia enterocolitica Drugs 0.000 description 37
- 241000606665 Anaplasma marginale Species 0.000 description 36
- 241000193155 Clostridium botulinum Species 0.000 description 36
- 241000193468 Clostridium perfringens Species 0.000 description 36
- 241000228404 Histoplasma capsulatum Species 0.000 description 36
- 241000233872 Pneumocystis carinii Species 0.000 description 36
- 241000193998 Streptococcus pneumoniae Species 0.000 description 36
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 36
- 241000193163 Clostridioides difficile Species 0.000 description 35
- 241000606856 Pasteurella multocida Species 0.000 description 34
- 229940051027 pasteurella multocida Drugs 0.000 description 34
- 229920002477 rna polymer Polymers 0.000 description 24
- 125000003275 alpha amino acid group Chemical group 0.000 description 19
- 229940088710 antibiotic agent Drugs 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 241000193403 Clostridium Species 0.000 description 12
- 241000191940 Staphylococcus Species 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000194033 Enterococcus Species 0.000 description 9
- 241000194017 Streptococcus Species 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 241000193830 Bacillus <bacterium> Species 0.000 description 8
- 241000186359 Mycobacterium Species 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000007876 drug discovery Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 241000607768 Shigella Species 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 206010011409 Cross infection Diseases 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000606860 Pasteurella Species 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 241001467018 Typhis Species 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032163 Emerging Communicable disease Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091030145 Retron msr RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000031650 Surgical Wound Infection Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241000606646 Anaplasma Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000036209 Intraabdominal Infections Diseases 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000021326 Ritter disease Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 229940038704 clostridium perfringens Drugs 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 210000003104 cytoplasmic structure Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108091092194 transporter activity Proteins 0.000 description 1
- 102000040811 transporter activity Human genes 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/26—Klebsiella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19107800P | 2000-03-21 | 2000-03-21 | |
| US60/191,078 | 2000-03-21 | ||
| US20684800P | 2000-05-23 | 2000-05-23 | |
| US60/206,848 | 2000-05-23 | ||
| US20772700P | 2000-05-26 | 2000-05-26 | |
| US60/207,727 | 2000-05-26 | ||
| US24257800P | 2000-10-23 | 2000-10-23 | |
| US60/242,578 | 2000-10-23 | ||
| US25362500P | 2000-11-27 | 2000-11-27 | |
| US60/253,625 | 2000-11-27 | ||
| US25793100P | 2000-12-22 | 2000-12-22 | |
| US60/257,931 | 2000-12-22 | ||
| US26930801P | 2001-02-16 | 2001-02-16 | |
| US60/269,308 | 2001-02-16 | ||
| PCT/US2001/009180 WO2001070955A2 (en) | 2000-03-21 | 2001-03-21 | Identification of essential genes in prokaryotes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001249345A1 true AU2001249345A1 (en) | 2001-10-03 |
Family
ID=27569239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001249345A Abandoned AU2001249345A1 (en) | 2000-03-21 | 2001-03-21 | Identification of essential genes in prokaryotes |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020061569A1 (OSRAM) |
| EP (1) | EP1268774A2 (OSRAM) |
| JP (1) | JP4852211B2 (OSRAM) |
| KR (1) | KR20020097200A (OSRAM) |
| AU (1) | AU2001249345A1 (OSRAM) |
| CA (1) | CA2404260A1 (OSRAM) |
| WO (1) | WO2001070955A2 (OSRAM) |
Families Citing this family (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11503619A (ja) * | 1996-01-19 | 1999-03-30 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | スタフィロコッカス・アウレウスのメチオニル−ｔＲＮＡシンセターゼ |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| JP2003506011A (ja) * | 1999-04-15 | 2003-02-18 | ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア | ソーターゼ遺伝子の同定 |
| US7101692B2 (en) * | 1999-04-15 | 2006-09-05 | The Regents Of The University Of California | Identification of sortase gene |
| US7125698B2 (en) * | 1999-08-09 | 2006-10-24 | Matthew Glenn | Polynucleotides, materials incorporating them, and methods for using them |
| CA2386235A1 (en) * | 1999-10-04 | 2001-04-12 | Merck & Co., Inc. | Mray gene and enzyme of pseudomonas aeruginosa |
| US6861516B1 (en) | 1999-10-04 | 2005-03-01 | Merck & Co., Inc. | MraY gene and enzyme of pseudomonas aeruginosa |
| US20020120408A1 (en) * | 2000-09-06 | 2002-08-29 | Kreiswirth Barry N. | System and method for tracking and controlling infections |
| US7349808B1 (en) | 2000-09-06 | 2008-03-25 | Egenomics, Inc. | System and method for tracking and controlling infections |
| WO2002034771A2 (en) | 2000-10-27 | 2002-05-02 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
| US20020107368A1 (en) * | 2000-12-07 | 2002-08-08 | Jing-Hui Tian | Helicobacter proteins, gene sequences and uses thereof |
| DK1355918T5 (da) | 2000-12-28 | 2012-02-20 | Wyeth Llc | Rekombinant beskyttelsesprotein af streptococcus pneumoniae |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| GB0107658D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| AU2002307448A1 (en) * | 2001-04-20 | 2002-11-05 | President And Fellows Of Harvard College | Methods and compositions for the modulation of biofilm formation |
| AU2002328215A1 (en) * | 2001-09-18 | 2003-04-01 | Affinium Pharmaceuticals, Inc. | Purified bacterial polypeptides involved in nucleic acid processing |
| AU2002328225A1 (en) * | 2001-09-21 | 2003-04-01 | Affinium Pharmaceuticals, Inc. | Bacterial polypeptides involved in protein processing |
| WO2003045985A2 (en) * | 2001-11-26 | 2003-06-05 | Affinium Pharmaceuticals, Inc. | Purified polypeptides involved in carbohydrate and coenzyme metabolism |
| AU2002331473A1 (en) * | 2001-09-25 | 2003-04-07 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from pseudomonas aeruginosa |
| WO2003029407A2 (en) * | 2001-09-26 | 2003-04-10 | Merck & Co., Inc. | Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof |
| EP1930420A1 (en) * | 2001-09-26 | 2008-06-11 | Merck & Co., Inc. | Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof |
| US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| EP1456380B1 (en) * | 2001-11-02 | 2012-04-18 | Giuliani International Limited | Smad7 inhibitors for the treatment of cns diseases |
| RU2229513C2 (ru) | 2001-11-23 | 2004-05-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" | Способ получения l-аминокислот, штамм escherichia coli - продуцент l-аминокислоты (варианты) |
| AU2002364771A1 (en) * | 2001-11-26 | 2003-06-10 | Affinium Pharmaceuticals, Inc. | Purified polypeptides involved in general metabolism as possible drug targets |
| TW200303919A (en) * | 2001-12-05 | 2003-09-16 | Hiroyuki Ohno | Cytotoxic protein and the use |
| US20030170694A1 (en) * | 2001-12-21 | 2003-09-11 | Daniel Wall | Stabilized nucleic acids in gene and drug discovery and methods of use |
| WO2003066849A2 (en) * | 2002-02-04 | 2003-08-14 | Affinium Pharmaceuticals, Inc. | Novel purified polypeptides from staphylococcus aureus |
| US6946267B2 (en) * | 2002-03-13 | 2005-09-20 | Dr. Chip Biotechnology Inc. | Method for detecting Staphylococcus aureus |
| WO2003087353A2 (en) * | 2002-04-08 | 2003-10-23 | Affinium Pharmaceuticals, Inc. | Purified polypeptides involved in membrane biogenesis |
| US20090252756A1 (en) * | 2002-04-02 | 2009-10-08 | Yaffa Mizrachi-Nebenzahl | Protein-based streptococcus pneumoniae vaccines |
| US8691243B2 (en) | 2002-04-02 | 2014-04-08 | Ben-Gurion University Of The Negev Research And Development Authority | Protein-based Streptococcus pneumoniae vaccine |
| AU2003213950A1 (en) * | 2002-04-08 | 2003-10-27 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from s. aureus, h. pylori and e. coli involved in cellular transport and metabolism |
| AU2003218563A1 (en) * | 2002-04-09 | 2003-10-27 | Affinium Pharmaceuticals, Inc. | Enolase polypeptides and structures |
| AU2003218934A1 (en) * | 2002-04-17 | 2003-11-03 | Affinium Pharmaceuticals, Inc. | Purified (3r)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase polypeptide from pseudomonas aeruginosa |
| AU2003229205A1 (en) * | 2002-05-31 | 2003-12-19 | Affinium Pharmaceuticals, Inc. | Bacterial polypeptides involved in viability |
| WO2003102544A2 (en) * | 2002-05-31 | 2003-12-11 | Cognosci, Inc. | Assays for measuring matrix metalloproteinase activities |
| US20060035365A1 (en) * | 2002-07-17 | 2006-02-16 | Hamelin Michael J | Method for identifying cellular growth inhibitors |
| WO2004013167A2 (en) * | 2002-08-01 | 2004-02-12 | Affinium Pharmaceuticals, Inc. | Purified polypeptides from enterococcus faecalis |
| AU2003278714A1 (en) * | 2002-08-20 | 2004-03-11 | Chiron Corporation | Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes |
| US20070053924A1 (en) * | 2002-08-26 | 2007-03-08 | Herve Tettelin | Conserved and specific streptococcal genomes |
| AU2003280247A1 (en) * | 2002-11-05 | 2004-06-07 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
| FR2846668B1 (fr) * | 2002-11-05 | 2007-12-21 | Univ Aix Marseille Ii | Identification moleculaire des bacteries du genre streptococcus et genres apparentes |
| AU2003280250A1 (en) * | 2002-11-05 | 2004-06-07 | Affinium Pharmaceuticals, Inc. | Crystal structures of bacterial thymidylate kinases |
| WO2004058812A2 (en) * | 2002-12-26 | 2004-07-15 | Affinium Pharmaceuticals, Inc. | Ribose-phosphate pyrophosphokinase polypeptides and structures |
| WO2004081206A2 (en) * | 2003-03-12 | 2004-09-23 | Affinium Pharmaceuticals, Inc. | Novel polypeptides encoded by essential bacterial genes |
| AU2003287825A1 (en) * | 2002-12-31 | 2004-07-22 | Affinium Pharmaceuticals, Inc. | Crystal structures of nh3-dependent nad synthetases |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US7618775B2 (en) * | 2003-04-17 | 2009-11-17 | The Scripps Research Institute | Expanding the eukaryotic genetic code |
| US20050026189A1 (en) * | 2003-05-29 | 2005-02-03 | Liangsu Wang | Microbial operons |
| JP4875490B2 (ja) * | 2003-07-31 | 2012-02-15 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物 |
| US8945589B2 (en) * | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
| EP1670505B1 (en) | 2003-09-18 | 2012-11-14 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Dna promoters and anthrax vaccines |
| ATE520709T1 (de) | 2003-09-19 | 2011-09-15 | Epitopix Llc | Campylobacter-polypeptide und verwendungsverfahren |
| US20050176033A1 (en) * | 2003-11-10 | 2005-08-11 | Klyachko Elena V. | Mutant phosphoribosylpyrophosphate synthetase and method for producing L-histidine |
| WO2005108626A2 (en) * | 2004-05-07 | 2005-11-17 | Replidyne, Inc. | Mutants of staphylococcal mrs and methods of use |
| JP2008507296A (ja) * | 2004-07-26 | 2008-03-13 | ナノスフェアー インコーポレイテッド | 混合培養物中でメチシリン耐性黄色ブドウ球菌とメチシリン感受性黄色ブドウ球菌とを区別する方法 |
| EP1784211A4 (en) | 2004-07-29 | 2010-06-30 | Novartis Vaccines & Diagnostic | IMMUNOGENIC COMPOSITIONS FOR GRAMPOSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE |
| US20060078952A1 (en) * | 2004-09-14 | 2006-04-13 | Carine Robichon | Method for identifying antimicrobial molecules which interfere with apolipoprotein N-acyltransferase activity |
| US20080095792A1 (en) * | 2004-09-17 | 2008-04-24 | Anderson Annaliesa S | Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus |
| CA2583803C (en) * | 2004-10-08 | 2014-11-25 | Giuliano Bensi | Immunogenic and therapeutic compositions for streptococcus pyogenes |
| DE102004055508A1 (de) * | 2004-11-17 | 2006-06-01 | Basf Ag | Verfahren zur Herstellung optisch aktiver Alkohole |
| ES2589927T3 (es) | 2005-01-21 | 2016-11-17 | Merck Sharp & Dohme Corp. | Polipéptidos para inducir una respuesta inmunitaria protectora contra Staphylococcus aureus |
| CN101142230A (zh) | 2005-01-21 | 2008-03-12 | 埃皮托皮克斯有限责任公司 | 耶尔森氏菌属物种的多肽及其使用方法 |
| AU2006214534B2 (en) | 2005-02-14 | 2012-07-19 | Epitopix, Llc | Polypeptides from Staphylococcus aureus and methods of use |
| GB0505949D0 (en) | 2005-03-23 | 2005-04-27 | Univ Sheffield | Polypeptides |
| NZ591415A (en) * | 2005-03-30 | 2012-10-26 | Novartis Vaccines & Diagnostic | Haemophilus influenzae type B |
| WO2007093848A2 (en) * | 2005-08-03 | 2007-08-23 | Affinium Pharmaceuticals, Inc. | Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori |
| US8945899B2 (en) | 2007-12-20 | 2015-02-03 | Butamax Advanced Biofuels Llc | Ketol-acid reductoisomerase using NADH |
| US7960312B2 (en) * | 2005-11-10 | 2011-06-14 | National University Of Corporation Hiroshima University | Method and agent for immobilizing protein via protein bound to silicon oxide-containing substance |
| WO2007106536A2 (en) | 2006-03-14 | 2007-09-20 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
| ATE522541T1 (de) * | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
| EP2074231B1 (en) * | 2006-09-14 | 2010-06-16 | Universitat De Girona | A method for specific detection of salmonella spp |
| FR2906532B1 (fr) * | 2006-09-28 | 2008-12-12 | Biomerieux Sa | Nouvel oligonucleotide marque |
| WO2008044599A1 (fr) * | 2006-10-06 | 2008-04-17 | Proteus Science Co., Ltd. | Polypeptide ayant une activité de ciblage d'un intestin présentant une inflammation, et son utilisation |
| JP2010508276A (ja) * | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 化膿連鎖球菌のための免疫原性組成物および治療組成物 |
| BRPI0808600A2 (pt) * | 2007-04-18 | 2018-12-26 | Du Pont | "método para a conversão de acetolactato em dihidroxi-isovalerato, método para a produção de isobutanol, célula hospedeira recombinante e método para a identificação e isolameno de uma construção genética" |
| US8017337B2 (en) | 2007-04-19 | 2011-09-13 | Molecular Detection, Inc. | Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria |
| JP2010183841A (ja) * | 2007-05-29 | 2010-08-26 | Ajinomoto Co Inc | Ｌ−アミノ酸の製造法 |
| KR20100072228A (ko) | 2007-08-31 | 2010-06-30 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| MX2010002773A (es) | 2007-09-12 | 2010-03-31 | Novartis Ag | Antigenos mutantes de gas57 y anticuerpos de gas57. |
| BRPI0821748A2 (pt) * | 2007-12-19 | 2019-09-24 | Basf Plant Science Gmbh | método para produzir uma planta com rendimento aumentado, molécula isolada de ácido nucleico, construção de ácido nucleico, vetor, processo para produzir um polipeptídeo, polipeptídeo, anticorpo, núcleo de célula de planta, célula de planta, tecido de planta, material de propagação, semente, pólen, progênie, ou uma parte de planta, ou uma planta com rendimento aumento, processo para a indentificação de um composto, método para a produção de uma composição agrícola, composição, polipeptídeo ou molécula de ácido nucleico, uso dos ácidos nucléicos, e, método para a indentificação de uma planta com um rendimento aumentado |
| DK2235046T3 (da) * | 2007-12-21 | 2012-10-29 | Novartis Ag | Mutante former af streptolysin-O |
| FI20075976A0 (fi) * | 2007-12-31 | 2007-12-31 | Finnzymes Oy | Menetelmät ja oligonukleotidit utaretulehdusta aiheuttavien bakteerien osoittamiseksi |
| WO2009100215A2 (en) | 2008-02-08 | 2009-08-13 | Mayo Foundation For Medical Education And Research | Detection of clostridium difficile |
| WO2009111337A1 (en) | 2008-03-03 | 2009-09-11 | Irm Llc | Compounds and compositions as tlr activity modulators |
| US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| KR100975956B1 (ko) * | 2008-08-08 | 2010-08-13 | 주식회사 콤슨테크놀러지 | 살균기능을 가지는 장애인용 이동장치 |
| US8637249B2 (en) * | 2008-11-14 | 2014-01-28 | Gen-Probe Incorporated | Compositions, kits and methods for detection of Campylobacter nucleic acid |
| JP2012509665A (ja) * | 2008-11-26 | 2012-04-26 | メルク・シャープ・エンド・ドーム・コーポレイション | スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド |
| CN105582524A (zh) * | 2009-03-23 | 2016-05-18 | 埃皮托皮克斯有限责任公司 | 多肽和含有革兰氏阳性多肽的免疫组合物及使用方法 |
| HUE026855T2 (en) | 2009-04-03 | 2016-07-28 | Univ Chicago | Compositions and methods related to protein a (spa) variants |
| US9517263B2 (en) | 2009-06-10 | 2016-12-13 | Glaxosmithkline Biologicals Sa | Benzonaphthyridine-containing vaccines |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| EA026401B1 (ru) | 2009-09-02 | 2017-04-28 | Новартис Аг | Иммуногенные композиции, содержащие модуляторы активности tlr |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| MX339146B (es) | 2009-12-15 | 2016-05-13 | Novartis Ag | Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos. |
| MX341395B (es) | 2010-03-23 | 2016-08-18 | Novartis Ag * | Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc. |
| KR101933226B1 (ko) | 2010-05-05 | 2018-12-28 | 뉴욕 유니버시티 | 스타필로코커스 아우레우스 류코시딘, 치료 조성물 및 그것의 용도 |
| SG186290A1 (en) | 2010-07-02 | 2013-01-30 | Univ Chicago | Compositions and methods related to protein a (spa) variants |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| JP6048932B2 (ja) * | 2010-12-28 | 2016-12-21 | 国立大学法人広島大学 | 酸化ケイ素と窒化ケイ素とを識別するポリペプチドおよびその利用 |
| MX347976B (es) | 2011-03-24 | 2017-05-22 | Butamax(Tm) Advanced Biofuels Llc | Celulas huesped y metodos para producir isobutanol. |
| WO2012136653A1 (en) * | 2011-04-08 | 2012-10-11 | Novvac Aps | Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| GB201116767D0 (en) | 2011-09-28 | 2011-11-09 | St George S Hospital Medical School | Treatment for mitrochondrial neurogastrointestinal encephalomyopathy |
| EP2773655A4 (en) * | 2011-10-31 | 2015-04-22 | Merck Sharp & Dohme | PROTECTION BASED ON STAPHYLOCOCCUS AUREUS SA2074 PROTEIN |
| DK2812434T3 (en) | 2012-02-09 | 2018-07-16 | Bavarian Nordic As | AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR-13 (TLR-13) |
| US9181568B2 (en) * | 2012-04-23 | 2015-11-10 | Exxonmobil Research And Engineering Company | Cell systems and methods for improving fatty acid synthesis by expression of dehydrogenases |
| PL2844275T3 (pl) | 2012-04-26 | 2021-03-08 | University Of Chicago | Koagulazy gronkowcowe stanowiące antygeny i sposoby ich zastosowania |
| WO2013176909A2 (en) | 2012-05-11 | 2013-11-28 | Butamax Advanced Biofuels Llc | Ketol-acid reductoisomerase enzymes and methods of use |
| WO2014011645A1 (en) | 2012-07-10 | 2014-01-16 | Merck Sharp & Dohme Corp. | Protective vaccine based on staphylococcus aureus sa2493 protein |
| KR20150056540A (ko) * | 2012-09-19 | 2015-05-26 | 노파르티스 아게 | 백신으로서의 클로스트리듐 디피실 폴리펩티드 |
| US9512408B2 (en) | 2012-09-26 | 2016-12-06 | Butamax Advanced Biofuels Llc | Polypeptides with ketol-acid reductoisomerase activity |
| NZ707035A (en) | 2012-10-17 | 2018-11-30 | Agronomique Inst Nat Rech | Gene signatures of inflammatory disorders that relate to the liver |
| EP2950819B1 (en) | 2013-02-01 | 2018-03-28 | GlaxoSmithKline Biologicals SA | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
| KR20150013092A (ko) * | 2013-07-26 | 2015-02-04 | 삼성전자주식회사 | 숙신산 생산능이 향상된 박테리아 세포 및 이를 이용하여 숙신산을 생산하는 방법 |
| CA2919383A1 (en) | 2013-08-05 | 2015-02-12 | Greenlight Biosciences, Inc. | Engineered proteins with a protease cleavage site |
| US10100093B2 (en) | 2013-12-31 | 2018-10-16 | Epitopix Llc | Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use |
| US20170049848A1 (en) * | 2014-05-06 | 2017-02-23 | Virginia Commonwealth University | Target for Firmicutes and Related Bacteria: The PRP Protease |
| HRP20191671T1 (hr) | 2014-05-09 | 2019-12-13 | Immatics Biotechnologies Gmbh | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| FR3024903A1 (fr) | 2014-08-14 | 2016-02-19 | Biomerieux Sa | Procede de quantification d'au moins un groupe de microorganismes par spectrometrie de masse |
| TWI649331B (zh) * | 2015-06-11 | 2019-02-01 | 國立中興大學 | 鮑氏不動桿菌（Ａｃｉｎｅｔｏｂａｃｔｅｒ ｂａｕｍａｎｎｉｉ）多胜肽抗原及其抗體以及編碼該抗原之核酸 |
| CN108368500B (zh) | 2015-10-02 | 2023-05-26 | 犹他大学研究基金会 | 用于可调整核糖体翻译速度的组成物和使用方法 |
| US10166280B2 (en) | 2016-06-08 | 2019-01-01 | Epitopix, Llc | Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use |
| KR102050870B1 (ko) * | 2017-04-06 | 2019-12-02 | 포항공과대학교 산학협력단 | 무항생제 플라스미드 유지 시스템에서 플라스미드 카피 수의 정량적 조절 방법 |
| CN111867623B (zh) | 2018-02-12 | 2024-06-04 | 英尼穆内公司 | Toll样受体配体 |
| US12018327B2 (en) | 2018-03-01 | 2024-06-25 | The Regents Of The University Of California | Methods and compositions relating to epoxide hydrolase genes |
| US12514914B2 (en) | 2019-05-14 | 2026-01-06 | The University Of Chicago | Methods and compositions comprising Staphylococcus protein a (SpA) variants |
| CA3148183C (en) * | 2019-08-28 | 2024-10-15 | Inner Mongolia Eppen Biotech Co., Ltd. | RECOMMENDED STRAIN BASED ON ESCHERICHIA COLI AND ITS CONSTRUCTION PROCESS AND APPLICATION |
| CA3153902A1 (en) | 2019-10-16 | 2021-04-22 | Pardis SABETI | Engineered muscle targeting compositions |
| JP7471688B2 (ja) * | 2019-12-03 | 2024-04-22 | 中國醫藥大學 | オリゴペプチド、検出キット及び医薬組成物 |
| US20230287437A1 (en) * | 2020-06-05 | 2023-09-14 | Modernatx, Inc. | Bacterial strains for dna production |
| KR20230098825A (ko) | 2020-11-04 | 2023-07-04 | 엘리고 바이오사이언스 | 씨. 아크네스 개체군에게 dna 페이로드의 원위치 전달을 위한 파지-유래 입자 |
| EP4399316A4 (en) * | 2021-09-08 | 2025-11-12 | Broad Inst Inc | MODIFIED FORMS FOR TARGETING THE CENTRAL NERVOUS SYSTEM AND MUSCLES |
| CN114032313B (zh) * | 2021-11-18 | 2024-09-17 | 广东海洋大学 | 一种评估、检测和/预测耗牛的牛肉品质性状的方法 |
| EP4516310A1 (en) * | 2022-04-28 | 2025-03-05 | The University of Tokyo | Bacteriolytic agent against enterococcus faecalis |
| EP4662323A2 (en) * | 2023-02-09 | 2025-12-17 | Kate Therapeutics, Inc. | Muscle targeted capsids |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5872104A (en) * | 1994-12-27 | 1999-02-16 | Oridigm Corporation | Combinations and methods for reducing antimicrobial resistance |
| CA2269658A1 (en) * | 1996-11-13 | 1998-05-22 | Qbi Enterprises, Ltd. | Gene identification method |
| AU735444B2 (en) * | 1997-05-06 | 2001-07-05 | Human Genome Sciences, Inc. | (Enterococcus faecalis) polynucleotides and polypeptides |
| US6610539B1 (en) * | 1997-07-10 | 2003-08-26 | Genesense Technologies, Inc. | Antisense oligonucleotide sequences as inhibitors of microorganisms |
| US6171838B1 (en) * | 1997-08-13 | 2001-01-09 | Smithkline Beecham Corporation | ratB |
| US6300318B1 (en) * | 1997-09-16 | 2001-10-09 | Peter E. Nielsen | Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor |
| US20020115217A1 (en) * | 1997-10-02 | 2002-08-22 | Smithkline Beecham Corporation | Whole cell assay |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| JP2002524069A (ja) * | 1998-09-09 | 2002-08-06 | ミレニアム ファーマシューティカルズ インク． | 必須細菌遺伝子およびその使用 |
-
2001
- 2001-03-21 WO PCT/US2001/009180 patent/WO2001070955A2/en not_active Ceased
- 2001-03-21 KR KR1020027012285A patent/KR20020097200A/ko not_active Withdrawn
- 2001-03-21 US US09/815,242 patent/US20020061569A1/en not_active Abandoned
- 2001-03-21 AU AU2001249345A patent/AU2001249345A1/en not_active Abandoned
- 2001-03-21 CA CA002404260A patent/CA2404260A1/en not_active Abandoned
- 2001-03-21 EP EP01922557A patent/EP1268774A2/en not_active Withdrawn
- 2001-03-21 JP JP2001569338A patent/JP4852211B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001070955A3 (en) | 2002-08-01 |
| KR20020097200A (ko) | 2002-12-31 |
| WO2001070955A8 (en) | 2004-04-15 |
| WO2001070955A2 (en) | 2001-09-27 |
| EP1268774A2 (en) | 2003-01-02 |
| JP4852211B2 (ja) | 2012-01-11 |
| US20020061569A1 (en) | 2002-05-23 |
| CA2404260A1 (en) | 2001-09-27 |
| JP2004516805A (ja) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020061569A1 (en) | Identification of essential genes in prokaryotes | |
| US20040029129A1 (en) | Identification of essential genes in microorganisms | |
| WO2002077183A2 (en) | Identification of essential genes in microorganisms | |
| US6720139B1 (en) | Genes identified as required for proliferation in Escherichia coli | |
| AU2277401A (en) | Genes identified as required for proliferation of e. coli | |
| WO2000044906A2 (en) | GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI) | |
| Ronish et al. | Recognition of extracellular DNA by type IV pili promotes biofilm formation by Clostridioides difficile | |
| US7629141B2 (en) | Essential and important genes of Pseudomonas aeruginosa and the use thereof to design or identify antibacterial agents | |
| US6589738B1 (en) | Genes essential for microbial proliferation and antisense thereto | |
| US20030170694A1 (en) | Stabilized nucleic acids in gene and drug discovery and methods of use | |
| EP1178052A2 (en) | Genes identified as required for proliferation in Escherichia coli | |
| US20050026189A1 (en) | Microbial operons | |
| JP2005508140A (ja) | エンジイン環構造の生合成に関与する遺伝子及びタンパク質 | |
| US7258995B2 (en) | Compositions and methods for affecting virulence determinants in bacteria | |
| Tsujimoto et al. | Cloning and expression of the major porin protein gene opcP of Burkholderia (formerly Pseudomonas) cepacia in Escherichia coli | |
| Kamal et al. | The TolC-like protein of Neisseria meningitidis is required for extracellular production of the repeats-in-toxin toxin FrpC but not for resistance to antimicrobials recognized by the Mtr efflux pump system | |
| CA2365929A1 (en) | Novel method for identifying antibacterial compounds | |
| US7390620B2 (en) | Screening method for anti-microbial drug targets by genome-saturating mutagenesis (GSM) | |
| CA2366359A1 (en) | Novel essential bacterial genes and their proteins | |
| Holbourn | Structural studies on bacterial toxins | |
| Jo | Two novel outer membrane proteins involved in intrinsic aminoglycoside resistence in Pseudomonas aeruginosa | |
| Stymest | Interaction of model peptides with the peptidyl-prolyl cis/trans isomerases SurA and PpiD | |
| Şahin | Molecular Characterization of the ATPase component of a putative ABC type transporter in Moraxella catarrhalis | |
| EP1499732A2 (en) | Essential and important genes of pseudomonas aeroginosa and the use thereof to design or identify antibacterial agents | |
| CA2445692A1 (en) | Compositions, methods and systems for the discovery of enediyne natural products |